Læknablaðið - 15.06.2011, Síða 13

'Stei'- ■■ ■

Áhrifarík stjórn á jákvæðum og
neikvæðum einkennum án þess að
hætta líkamlegri heilsu14
í meðferð geðklofa
(ziprasidone HCI)
Því sjálfstraust skiptir máli
Heimitdir: 1. Alptekin K, et al. Efþcacy and tolerability of switching to ziprasidone from olanzapine, risperidone or haloperidol:
an international, multicenter study. Int Clin Psychopharmacol. 2009;24(5):229-38. 2. Weiden PJ, et al. Effectiveness of switching to
ziprasidone for stable but symptomatic outpatients with schizophrenia. J Clin Psychiatry. 2003;64(5):58o-8. 3. Kahn RS, et al.
Effectiveness of antipsychotic drugs in þrst-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial.
Lancet. 2008;371:1085-97. 4. Grootens KP, et al. Ziprasidone vs olanzapine in recent-onset schizophrenia and schizoaffective disorder:
Results of an 8-week double-blind randomized controlled trial. Schizophr Bull. Advanced Access published June 19 2009.
Sérlyfjatexti á bls. 390